Nuclear medicine firm Curium has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for its copper-64 (Cu-64) PSMA I&T diagnostic radiopharmaceutical.
Designed to detect and localize metastatic prostate cancer on PET exams, Cu-64 PSMA I&T binds to prostate-specific membrane antigen (PSMA), according to the vendor. The radiopharmaceutical would enable imaging sites in the U.S. to provide PSMA-based prostate cancer imaging without local cyclotron production or access to a nearby gallium generator, Curium said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
